MA51222A - Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production - Google Patents

Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Info

Publication number
MA51222A
MA51222A MA051222A MA51222A MA51222A MA 51222 A MA51222 A MA 51222A MA 051222 A MA051222 A MA 051222A MA 51222 A MA51222 A MA 51222A MA 51222 A MA51222 A MA 51222A
Authority
MA
Morocco
Prior art keywords
pyrimidinylamino
polymorphs
production processes
solid forms
pyrazole compound
Prior art date
Application number
MA051222A
Other languages
English (en)
Inventor
Travis Remarchuk
Anantha Sudhakar
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA51222A publication Critical patent/MA51222A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051222A 2017-11-21 2018-11-20 Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production MA51222A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762589276P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
MA51222A true MA51222A (fr) 2020-10-07

Family

ID=66631734

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051222A MA51222A (fr) 2017-11-21 2018-11-20 Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Country Status (24)

Country Link
US (3) US10370361B2 (fr)
EP (1) EP3717473B1 (fr)
JP (1) JP7303821B2 (fr)
KR (1) KR102878525B1 (fr)
CN (1) CN111819174A (fr)
AR (1) AR113893A1 (fr)
AU (1) AU2018372180B2 (fr)
CA (1) CA3083022A1 (fr)
CL (1) CL2020001346A1 (fr)
CO (1) CO2020006206A2 (fr)
CR (1) CR20200216A (fr)
EA (1) EA202091279A1 (fr)
ES (1) ES2975319T3 (fr)
IL (1) IL274824A (fr)
JO (1) JOP20200128A1 (fr)
MA (1) MA51222A (fr)
MX (1) MX2020005332A (fr)
MY (1) MY209751A (fr)
PE (1) PE20210157A1 (fr)
PH (1) PH12020550700A1 (fr)
SG (1) SG11202004733WA (fr)
TW (1) TWI823878B (fr)
UA (1) UA126414C2 (fr)
WO (1) WO2019104086A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210157A1 (es) * 2017-11-21 2021-01-26 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion
US11834438B2 (en) 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
KR20230097093A (ko) 2020-10-29 2023-06-30 머크 샤프 앤드 돔 엘엘씨 Lrrk2 억제제로서의 n-연결된 이소퀴놀린 아미드, 제약 조성물 및 그의 용도
WO2023174946A1 (fr) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode précoce et non invasive d'évaluation du risque de maladie de parkinson chez un sujet
US12272712B2 (en) 2022-05-14 2025-04-08 Xintec Inc. Chip package and method for forming a chip package having first and second stack of dummy metal layers surround the sensing region

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
SG189043A1 (en) * 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
CA2850594C (fr) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives aminopyrimidiniques utilises comme modulateurs de lrrk2
US8791130B2 (en) 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
MX349556B (es) 2011-11-29 2017-08-03 Genentech Inc Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CN104271569B (zh) * 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
EP2844658B1 (fr) 2012-05-03 2019-03-20 Genentech, Inc. Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2 destinés à être utilisés dans le traitement de la maladie de parkinson
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
PE20210157A1 (es) * 2017-11-21 2021-01-26 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion

Also Published As

Publication number Publication date
MX2020005332A (es) 2021-01-08
CR20200216A (es) 2021-03-19
MY209751A (en) 2025-07-31
CA3083022A1 (fr) 2019-05-31
WO2019104086A1 (fr) 2019-05-31
EA202091279A1 (ru) 2020-08-19
JOP20200128A1 (ar) 2020-05-21
EP3717473B1 (fr) 2024-01-10
NZ764730A (en) 2024-11-29
US20190315723A1 (en) 2019-10-17
KR20200089713A (ko) 2020-07-27
BR112020010215A2 (pt) 2020-11-03
TW201925190A (zh) 2019-07-01
US10370361B2 (en) 2019-08-06
US11427571B2 (en) 2022-08-30
KR102878525B1 (ko) 2025-10-31
TWI823878B (zh) 2023-12-01
PE20210157A1 (es) 2021-01-26
ES2975319T3 (es) 2024-07-04
EP3717473A4 (fr) 2021-07-07
IL274824A (en) 2020-07-30
CO2020006206A2 (es) 2020-08-10
EP3717473A1 (fr) 2020-10-07
US20210087176A1 (en) 2021-03-25
AR113893A1 (es) 2020-06-24
US10851088B2 (en) 2020-12-01
JP7303821B2 (ja) 2023-07-05
UA126414C2 (uk) 2022-09-28
PH12020550700A1 (en) 2021-04-12
CL2020001346A1 (es) 2020-11-20
US20190194170A1 (en) 2019-06-27
SG11202004733WA (en) 2020-06-29
CN111819174A (zh) 2020-10-23
AU2018372180B2 (en) 2023-08-17
JP2021504450A (ja) 2021-02-15
AU2018372180A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MA51222A (fr) Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production
EP3663307A4 (fr) Procédé de production d'un composé aryle radiomarqué
EP3472168A4 (fr) Formes cristallines d'un composé de triazolopyrimidine
EP3349587A4 (fr) Procédé de préparation d'un composé antifongique
EP3294865A4 (fr) Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3473625A4 (fr) Procédé de préparation d'un composé de pyrrolopyrimidine chiral
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
HUE059670T2 (hu) Eljárás új nitrogén-tartalmú vegyület vagy sója és intermedierjei elõállítására
EP3354677A4 (fr) Procédé de production d'un copolymère de polycarbonate-polyorganosiloxane
EP3768690A4 (fr) Formes cristallines et procédés de production de formes cristallines d'un composé
EP3632441A4 (fr) Procédé de production d'un composé optiquement actif
EP3647316A4 (fr) Procédé de production d'édulcorant à base d'allulose
MA41203A (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA50647A (fr) Procédé de régulation d'un puits
EP3623378A4 (fr) Procédé de production d'un composé organique cyclique
DK3668835T3 (da) Fremgangsmåde til fremstilling af en monothiocarbonatforbindelse
EP3693161A4 (fr) Procédé de production d'un stratifié, et stratifié
EP3643694A4 (fr) Procédé de production de composé de butadiène
EP3715338A4 (fr) Procédé de décomposition d'un sous-produit phénolique
EP3585822A4 (fr) Procédés de production de compositions de polyisobutylène
EP3423402A4 (fr) Procédé de synthèse de nanodiamants
EP3447042A4 (fr) Procédé de production de 1,2-dichlorohexafluorocyclopentène
SI3325453T1 (sl) Postopki kemijske sinteze substituiranih 10H-fenotiazin-3,7-diaminskih spojin
EP3584356A4 (fr) Semi-conducteur composé et procédé de production associé